Tags: cancer

Online Presentations (21-40 of 81)

  1. [Illinois] Cancer Community Symposium 2012: Materials Science vs. Metastasis

    09 May 2012 | | Contributor(s):: Daniel A. Heller

    Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer,...

  2. [Illinois] Cancer Community Symposium 2012: Chemical Imaging for Histopathology: An Emerging Route for Molecular and Structural Analysis of Tissues

    09 May 2012 | | Contributor(s):: Michael Walsh

    Mid-Infrared (IR) spectroscopic imaging is an emerging approach to derive chemical images from tissues based on their inherent biochemistry. Histologic diagnosis is the gold standard for evaluating the presence and severity of most diseases. Current histopathological techniques use of panel of...

  3. [Illinois] Cancer Community Symposium 2012: Panel Discussion

    09 May 2012 | | Contributor(s)::

    Please join us for a panel discussion on the social impact of cancer and how it affects patients, providers, clinicians, and researchers alike. We are fortunate to feature Leslie Hammersmith (moderator), Jennifer Smith, and Patience Anders from the local Young Survival Coalition, as well as an...

  4. [Illinois] Cancer Community Symposium 2012: Understanding and Targeting Transcription in Hematological Malignancies

    09 May 2012 | | Contributor(s):: Jonathan D. Licht

    Abnormalities in the epigenetic regulation of chromatin structure and function can lead to aberrant gene expression and cancer development. Epigenetic regulators can be affected by chromosomal rearrangement, point mutations, deletions and amplifications in cancer. The result may be changes in...

  5. [Illinois] Cancer Community Symposium 2012: The Inhibitory Effects of the Antifibrotic Drug Halofuginone on Uterine Leiomyoma Smooth Muscle Cells

    09 May 2012 | | Contributor(s):: Faezeh Koohestani

    Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are costly and have significant side effects. In an effort to develop alternative therapeutic strategies,...

  6. [Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling

    09 May 2012 | | Contributor(s):: Elvira de Mejia

    Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon...

  7. [Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)

    09 May 2012 | | Contributor(s):: Jennifer Stone

    Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...

  8. [Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents

    09 May 2012 | | Contributor(s):: Richard B. Jones

    A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer...

  9. [Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations

    09 May 2012 | | Contributor(s):: Jack Pu Hou

    One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...

  10. [Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer

    09 May 2012 | | Contributor(s):: Mary Jo Laws

    We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian...

  11. [Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research

    09 May 2012 | | Contributor(s):: John F. McDonald

    The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...

  12. [Illinois] Cancer Community Symposium 2012: Closing Address and Awards

    09 May 2012 | | Contributor(s):: Rohit Bhargava

    Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...

  13. KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor

    07 Dec 2011 | | Contributor(s):: Youngro Byun

    Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application due to its unsatisfactory therapeutic effects and a strong anticoagulant activity, which induces...

  14. KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?

    06 Dec 2011 | | Contributor(s):: J. Paul Robinson

    Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions

  15. KIST/PU Designing a Research Program Around Unmet Clinical Needs

    06 Dec 2011 | | Contributor(s):: Alyssa Panitch

  16. KIST/PU Theragnosis – A New Paradigm of Personalized Medicine

    06 Dec 2011 | | Contributor(s):: Ick Chan Kwon

    Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given...

  17. Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy

    05 Dec 2011 | | Contributor(s):: Li Tang

    Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer treatment. The size of these drug delivery vehicles has been strongly correlated with their in...

  18. Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements

    05 Dec 2011 | | Contributor(s):: Elise Corbin

    The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms through which a cell's physical properties influence cell growth, cell differentiation, cell cycle...

  19. BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention

    02 Dec 2011 | | Contributor(s):: Deborah W Knapp

    Guest lecturer: Deborah Knapp.

  20. Illinois 2011 NanoBiophotonics Summer School: Poster Day: Hadiyah Nicole Green

    29 Nov 2011 | | Contributor(s):: Hadiyah Nicole Green, Nadia Jassim

    Cancer laser treatment using gold nanorods.